Drug Profile
Research programme: STAT3 transcription factor inhibitors - Wyeth
Latest Information Update: 15 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Quinolines
- Mechanism of Action STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Sep 2011 Discontinued for Cancer in USA (unspecified route)
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 26 Mar 2009 Early research in Cancer in USA (unspecified route)